Literature DB >> 17109087

Neutralizing activity of bovine colostral antibody against verotoxin derived from enterohemorrhagic Escherichia coli O157:H7 in mice.

Takashi Kuribayashi1, Tetsurou Seita, Masafumi Fukuyama, Katsunori Furuhata, Masayuki Honda, Mariko Matsumoto, Hisase Seguchi, Shizuo Yamamoto.   

Abstract

The neutralization efficacy of bovine colostral antibody against verotoxin (VT) 1 and 2 was investigated. Cows were immunized with VT1 or VT2 fourteen times at 7-day intervals. A colostral antibody exhibiting high titers was obtained from immunized cows. Survival rates were evaluated in mice administered VT1 or VT2, and those infected with Escherichia coli (E. coli) O157:H7 producing VT1 or VT2. Survival rates after VT1 administration were 100% in the single-administration group, 90% in the repeat-administration group, and 78.6% in the control group. Survival rates after VT2 were 75.0% in the single-administration group, and 100% in the repeat-administration group. All mice in the control group died. Colostral antibody and fosfomycin (FOM) in the colostral antibody group and FOM and skim milk in the control group were administered three times per day for 5 days to mice infected with E. coli O157:H7 producing VT1 or VT2. Survival rates after inoculation with E. coli O157:H7 producing VT1 were 80.0% in the colostral antibody group, and 63.6% in the control group. Survival rates after inoculation with E. coli O157:H7 producing VT2 were 83.3% in the colostral antibody group, and 20.0% in the control group. The survival rate in mice without treatment following inoculation with E. coli O157:H7 producing VT2 was 88.2%. The survival rates in mice infected with E. coli O157:H7 strains producing VT1 or VT2 improved after administration of this colostral antibody, which exhibited neutralization efficacy against VT.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17109087     DOI: 10.1007/s10156-006-0470-y

Source DB:  PubMed          Journal:  J Infect Chemother        ISSN: 1341-321X            Impact factor:   2.211


  5 in total

1.  Bovine colostral antibody against verotoxin 2 derived from Escherichia coli O157:H7: resistance to proteases and effects in beagle dogs.

Authors:  Takashi Kuribayashi; Tetsuro Seita; Mariko Matsumoto; Katsunori Furuhata; Kazutoshi Tagata; Shizuo Yamamoto
Journal:  Comp Med       Date:  2009-04       Impact factor: 0.982

2.  Evaluation of biological safety in vitro and immunogenicity in vivo of recombinant Escherichia coli Shiga toxoids as candidate vaccines in cattle.

Authors:  Katharina Kerner; Philip S Bridger; Gabriele Köpf; Julia Fröhlich; Stefanie Barth; Hermann Willems; Rolf Bauerfeind; Georg Baljer; Christian Menge
Journal:  Vet Res       Date:  2015-04-10       Impact factor: 3.683

Review 3.  Approaches to treatment of emerging Shiga toxin-producing Escherichia coli infections highlighting the O104:H4 serotype.

Authors:  Elias A Rahal; Sukayna M Fadlallah; Farah J Nassar; Natalie Kazzi; Ghassan M Matar
Journal:  Front Cell Infect Microbiol       Date:  2015-03-18       Impact factor: 5.293

Review 4.  Treatment Strategies for Infections With Shiga Toxin-Producing Escherichia coli.

Authors:  Sabrina Mühlen; Petra Dersch
Journal:  Front Cell Infect Microbiol       Date:  2020-05-06       Impact factor: 5.293

Review 5.  The Role of Escherichia coli Shiga Toxins in STEC Colonization of Cattle.

Authors:  Christian Menge
Journal:  Toxins (Basel)       Date:  2020-09-21       Impact factor: 4.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.